# Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

> **NCT03382561** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 160 (actual)

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma
- Recurrent Lung Small Cell Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03382561
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2022-02-16
- **Final completion:** 2025-01-31
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382561, "Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03382561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*